The Fragment-Based Development of a Benzofuran Hit as a New Class of <i>Escherichia coli</i> DsbA Inhibitors

The Fragment-Based Development of a Benzofuran Hit as a New Class of <i>Escherichia coli</i> DsbA Inhibitors

A fragment-based drug discovery approach was taken to target the thiol-disulfide oxidoreductase enzyme DsbA from <i>Escherichia coli</i> (<i>Ec</i>DsbA). This enzyme is critical for the correct folding of virulence factors in many pathogenic Gram-negative bacteria, and small...

Full description

Bibliographic Details
Main Authors: Luke F. Duncan, Geqing Wang, Olga V. Ilyichova, Martin J. Scanlon, Begoña Heras, Belinda M. Abbott
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Molecules
Subjects:
fragment-based drug discovery
<i>escherichia coli</i>
antibiotic resistance
dsba inhibition
benzofuran
disulfide bond
bacterial virulence
Online Access:https://www.mdpi.com/1420-3049/24/20/3756

Similar Items

Similar Items